Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Lepu Biopharma Co's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02157 vs VRTX, REGN, RVMD: Buyback Yield % Comparison
For the Biotechnology subindustry, Lepu Biopharma Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lepu Biopharma Co Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lepu Biopharma Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Lepu Biopharma Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lepu Biopharma Co (HKSE:02157) has a Buyback Yield % of -6.65 as of Aug. 24, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Lepu Biopharma Co and its competitors. According to the industry distribution chart, Lepu Biopharma Co ranks #291 out of 704 companies in the Biotechnology industry, placing it in the top 41.3%.
Is Lepu Biopharma Co's Buyback Yield % too high?
Lepu Biopharma Co's current Buyback Yield % is -6.65. Based on the distribution chart, Lepu Biopharma Co ranks #291 out of 704 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lepu Biopharma Co has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lepu Biopharma Co's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lepu Biopharma Co ranks #291 out of 704 companies for Buyback Yield %. This puts Lepu Biopharma Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Lepu Biopharma Co and its competitors. Lepu Biopharma Co's current Buyback Yield % is -6.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lepu Biopharma Co stock overvalued right now?
Based on GuruFocus' analysis, Lepu Biopharma Co (HKSE:02157) is currently considered Possible Value Trap. The stock's GF Value™ is HK$16.73, compared to a current price of HK$3.83 — trading 77.1% below its estimated fair value. The current Buyback Yield % is -6.65. Lepu Biopharma Co's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Lepu Biopharma Co (HKSE:02157), the current Buyback Yield % is -6.65 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lepu Biopharma Co (HKSE:02157) Overvalued in 2026?
Based on GuruFocus' analysis, Lepu Biopharma Co stock appears to be undervalued.
The current stock price of HK$3.83 is trading 77.1% below its estimated GF Value™ of HK$16.73.
GuruFocus considers Lepu Biopharma Co to be Possible Value Trap.
Key valuation signals for HKSE:02157:
Buyback Yield %: -6.65
GF Value™: HK$16.73 vs. price of HK$3.83 (77.1% below fair value)
No single metric tells the full story. See the HKSE:02157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lepu Biopharma Co Ltd is focused on discovering, developing, and commercializing drug candidates in anti-tumor targeted therapy and oncology immunotherapy. Its commercial products include Puyouheng (Pucotenlimab Injection) and Meiyouheng (Becotatug Vedotin Injection). In addition, two other products, CMG901 and MRG007, have also been licensed out through its business development activities. Additionally, the company has several clinical-stage drug candidates and clinical-stage combination therapies of candidates, which are being developed as targeted therapeutics and immunotherapeutics. The various drug candidates in its pipeline include MRG003, MRG002, MRG004A, CG0070, MRG001, and MRG006A, among others. Geographically, the company generates maximum revenue from the Chinese mainland.
45GF Score
Get the complete analysis for HKSE:02157
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02157 has been successfully added to your 
